Commercial Collaboration Agreement for use of the PreTRM test within Elevance Health's network, with minimum purchase and payment commitments for the first three years.
| Officer | Age | In this role | 2025 pay | Source |
|---|---|---|---|---|
|
Zhenya Lindgardt
Also a director
President and Chief Executive Officer
|
52 | Not stated | $2,033,811 | |
|
Scott Gleason
Chief Financial Officer and Treasurer
Title from the Form 8-K dated Aug 31, 2026
|
Not stated | Not stated | Not reported | |
|
Lee Anderson
Chief Commercial Officer
|
62 |
Since 2025
1 year
|
Not reported | |
|
Tiffany Inglis
Chief Medical Officer
|
50 |
Since 2025
1 year
|
Not reported | |
|
Benjamin G. Jackson
General Counsel
|
47 |
Since 2021
5 years
|
Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
From the proxy statement filed Apr 24, 2026 · updated by the 8-Ks of Jun 1, 2026 and Jun 30, 2026
| Director | Age | On board | Independent | Committees | Other public boards | 2025 pay | Source |
|---|---|---|---|---|---|---|---|
|
Kim Kamdar
Board chair
|
58 |
2011
15 years
|
Not stated |
Compensation Committee · Chair
Nominating and Governance Committee
|
Seraphina Therapeutics, Truvian Sciences, Inc., Evofem Biosciences, Inc., Singular Genomics Systems | Not stated | |
|
Zhenya Lindgardt
CEO
|
52 |
2021
5 years
|
Not stated | None stated | None stated | Paid as CEO | |
|
Sandra A. J. Lawrence
|
68 |
2021
5 years
|
Not stated |
Audit Committee · Chair
|
Evergy, Inc. | $99,908 | |
|
Gregory C. Critchfield
|
74 |
2010
16 years
|
Not stated | None stated | None stated | $84,908 | |
|
Joshua Phillips
|
59 |
2011
15 years
|
Not stated |
Audit Committee
Compensation Committee
|
None stated | $97,408 | |
|
Jane F. Barlow
|
65 |
2022
4 years
|
Not stated |
Nominating and Governance Committee · Chair
|
None stated | $93,408 | |
|
Mansoor Raza Mirza
|
65 |
2014
12 years
|
Not stated |
Nominating and Governance Committee
|
None stated | $88,908 | |
|
Mark Capone
Joined Jul 1, 2026
|
- | - | Independent |
Compensation Committee
|
- | - |
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.
Commercial Collaboration Agreement for use of the PreTRM test within Elevance Health's network, with minimum purchase and payment commitments for the first three years.
Laboratory Services Agreement for provision of PreTRM tests and related services during the PRIME study.
Amended side letter giving Baker Bros. the right to nominate one Investor Designee to the board while it owns at least 19.9% of total voting power.
Fourth Amended and Restated Investors' Rights Agreement granting registration rights for resale of their shares.
Entities affiliated with Baker Bros. purchased Pre-Funded Warrants in the public offering to purchase 11,250,000 shares of Class A common stock at $3.9999 per warrant.
Chione Ltd. purchased 625,000 shares of Class A common stock in the public offering at $4.00 per share.
Consulting agreement (Statement of Work #1) for third-party payer engagement services; fees incurred under it.
Service agreement (Statement of Work #2) for pursuing third-party payer coverage for PreTRM; fees incurred before termination.
Loading...